{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T14:30:33Z","timestamp":1787495433753,"version":"build-2736575974"},"reference-count":34,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2016,3,21]],"date-time":"2016-03-21T00:00:00Z","timestamp":1458518400000},"content-version":"vor","delay-in-days":20,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005205","name":"Janssen Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J American Geriatrics Society"],"published-print":{"date-parts":[[2016,3]]},"abstract":"\n Objectives<\/jats:title>\n To compare the efficacy and safety of canagliflozin, a sodium glucose co\u2010transporter 2 inhibitor developed to treat type 2 diabetes mellitus (T2DM), in individuals younger than 75 and those aged 75 and older.<\/jats:p>\n <\/jats:sec>\n \n Design<\/jats:title>\n Randomized Phase 3 studies.<\/jats:p>\n <\/jats:sec>\n \n Setting<\/jats:title>\n International study centers.<\/jats:p>\n <\/jats:sec>\n \n Participants<\/jats:title>\n Adults with T2DM.<\/jats:p>\n <\/jats:sec>\n \n Measurements<\/jats:title>\n \n Changes from baseline in glycosylated hemoglobin (HbA\n 1c<\/jats:sub>\n ), fasting plasma glucose (\n FPG<\/jats:styled-content>\n ), blood pressure (\n BP<\/jats:styled-content>\n ), and body weight were measured. Efficacy was evaluated using pooled data from six randomized, double\u2010blind, placebo\u2010controlled studies (N\u00a0=\u00a04,158; n\u00a0=\u00a03,975 aged <75, n\u00a0=\u00a0183 aged \u226575). Safety was assessed based on adverse event (\n AE<\/jats:styled-content>\n ) reports from eight randomized, double\u2010blind, placebo\u2010 and active\u2010controlled studies (N\u00a0=\u00a09,439; n\u00a0=\u00a08,949 aged <75, n\u00a0=\u00a0490 aged \u226575).\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Canagliflozin 100 and 300\u00a0mg were associated with placebo\u2010subtracted mean reductions in HbA\n 1c<\/jats:sub>\n in participants younger than 75 (\u22120.69% and \u22120.85%, respectively) and aged 75 and older (\u22120.65% and \u22120.55%, respectively). Dose\u2010related reductions in\n FPG<\/jats:styled-content>\n , body weight, and\n BP<\/jats:styled-content>\n were seen with canagliflozin 100 and 300\u00a0mg in participants in both age groups. Overall\n AE<\/jats:styled-content>\n incidence was 67.1% with canagliflozin 100\u00a0mg, 68.6% with canagliflozin 300\u00a0mg, and 65.9% with non\u2010canagliflozin (pooled group of comparators in all studies) in participants younger than 75, and 72.4%, 79.1%, and 72.3%, respectively, in those aged 75 and older, with a similar safety profile in both groups. The incidence of volume depletion\u2013related\n AE<\/jats:styled-content>\n s was 2.2%, 3.1%, and 1.4% in participants younger than 75 with canagliflozin 100 and 300\u00a0mg and non\u2010canagliflozin, respectively, and 4.9%, 8.7%, and 2.6%, respectively, in those aged 75 and older.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n \n Canagliflozin improved glycemic control, body weight, and\n BP<\/jats:styled-content>\n in participants aged 75 and older. The overall incidence of\n AE<\/jats:styled-content>\n s was high across treatment groups in participants aged 75 and older and higher than in those younger than 75. The safety profile of canagliflozin was generally similar in both age groups, with a higher incidence of\n AE<\/jats:styled-content>\n s related to volume depletion observed with canagliflozin in participants aged 75 and older than in those younger than 75. These findings support canagliflozin, starting with the 100\u2010mg dose, as an effective therapeutic option for older adults with T2DM.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1111\/jgs.14028","type":"journal-article","created":{"date-parts":[[2016,3,22]],"date-time":"2016-03-22T07:23:58Z","timestamp":1458631438000},"page":"543-552","source":"Crossref","is-referenced-by-count":76,"title":["Efficacy and Safety of Canagliflozin in Individuals Aged 75 and Older with Type 2 Diabetes Mellitus: A Pooled Analysis"],"prefix":"10.1111","volume":"64","author":[{"given":"Alan J.","family":"Sinclair","sequence":"first","affiliation":[{"name":"Foundation for Diabetes Research in Older People Diabetes Frail, Gerrards Cross Bucks UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"Bode","sequence":"additional","affiliation":[{"name":"Atlanta Diabetes Associates Atlanta Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stewart","family":"Harris","sequence":"additional","affiliation":[{"name":"University of Western Ontario London Ontario"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ujjwala","family":"Vijapurkar","sequence":"additional","affiliation":[{"name":"Janssen Research & Development, LLC Raritan New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wayne","family":"Shaw","sequence":"additional","affiliation":[{"name":"Janssen Research & Development, LLC Raritan New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehul","family":"Desai","sequence":"additional","affiliation":[{"name":"Janssen Research & Development, LLC Raritan New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Meininger","sequence":"additional","affiliation":[{"name":"Janssen Research & Development, LLC Raritan New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,3,21]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-1801"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-2441"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)68967-8"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcjd.2013.01.045"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)61676-1"},{"key":"e_1_2_6_7_1","first-page":"S1","article-title":"Standards of medical care in diabetes\u20142015","volume":"38","author":"American Diabetes Association","year":"2015","journal-title":"Diabetes Care"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jamda.2012.04.012"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)61055-7"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc11-1926"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12428"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12054"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-2491"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12090"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.3810\/hp.2013.04.1020"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60683-2"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-013-3039-1"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.12322"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2013.850066"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12348"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12273"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-2762"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-4205"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2012.01558.x"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.88"},{"key":"e_1_2_6_26_1","first-page":"419","article-title":"Ageing and the glomerular filtration rate: Truths and consequences","volume":"120","author":"Glassock RJ","year":"2009","journal-title":"Trans Am Clin Climatol Assoc"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1159\/000364909"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6823-14-37"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.3810\/pgm.2014.05.2753"},{"key":"e_1_2_6_30_1","volume-title":"INVOKANA (Canagliflozin) Tablets, for Oral Use [Package Insert]","year":"2014"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-015-0117-z"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-1237"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2013.05.007"},{"key":"e_1_2_6_34_1","volume-title":"INVOKANA (Canagliflozin) 100\u2010mg Film\u2010Coated Tablets, for Oral Use [Summary of Product Characteristics]","year":"2014"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-3167"}],"container-title":["Journal of the American Geriatrics Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjgs.14028","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jgs.14028","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jgs.14028","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/agsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jgs.14028","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T17:39:51Z","timestamp":1762191591000},"score":1,"resource":{"primary":{"URL":"https:\/\/agsjournals.onlinelibrary.wiley.com\/doi\/10.1111\/jgs.14028"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["10.1111\/jgs.14028"],"URL":"https:\/\/doi.org\/10.1111\/jgs.14028","archive":["Portico"],"relation":{},"ISSN":["0002-8614","1532-5415"],"issn-type":[{"value":"0002-8614","type":"print"},{"value":"1532-5415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3]]}}}